A Chat with Anat

ApotheCom
A Chat with Anat

"A Chat with Anat" is a series for ophthalmologists who are interested in improving delivery of care for patients living with retinal disease, and for those interested in clinically-challenging situations or controversies in care. I’m Professor Anat Loewenstein, Chair of the Department of Ophthalmology at Tel Aviv Sourasky Medical Centre in Israel, and Professor of Ophthalmology and Vice Dean at Tel Aviv University. For each episode, I will be joined by internationally renowned colleagues to discuss these important topics. This podcast series is sponsored and organized by Bayer and produced by ApotheCom. This podcast series is produced and funded by Bayer. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise. This is not intended for UK audiences. 

  1. The Hot Seat

    JUL 8

    The Hot Seat

    In this special episode, the roles have been reversed! Your host is Professor Tariq Aslam, Professor of Ophthalmology and Interface Technologies at the University of Manchester in the United Kingdom, who asked me questions sent in by my retinal community colleagues. Tune in to hear how I balance my busy career with my well-being, the pep talks I give to nervous first-time patients and trainees, myths about retinal disease I’d like to erase forever, and even an embarrassing moment in my career!  This episode was recorded live at the Joint Vision Academy Steering Committee and Barometer Leadership Coalition Meeting in Rome. To learn more about these programs and access the important materials and training resources for clinicians and patients to improve patient-focused care and clinical practice, visit the Vision Academy Program website and nAMD Barometer Program website. If you enjoyed this episode, SUBSCRIBE to “A Chat with Anat” to make sure you never miss an episode!  Speaker disclosures: Professor Anat Loewenstein Consultant: 4DMT, Abbvie, Astellas, Aviceda, Bayer, Beyeonics, Boehringer Ingelheim; Eyepoint, NotalVision, Ocular Therapeutix, Oculis, Ocuphire, Opthea, Roche, and Voiant. Professor Tariq Aslam Grants, speaker fees, and travel: Bayer, Boehringer Ingelheim, Canon, Heidelberg, Novartis, Roche, Thea, and Topcon. July 2025 PP-PF-OPHT-ALL-0230-1 This podcast series is intended for HCPs, and is not intended for UK audiences. Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing. This podcast series is produced and funded by Bayer. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise. The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer. The activities of the Barometer Program are funded and facilitated by Bayer where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program. The Vision Academy is a group of over 80 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer.

    25 min
  2. Monitoring the fellow eye in nAMD

    MAY 12

    Monitoring the fellow eye in nAMD

    My guest for this special episode is Professor Paolo Lanzetta, Chair of the Department of Ophthalmology at the University of Udine, Italy. In this episode, Paolo and I explore the importance of monitoring the fellow eye of patients with nAMD. We also discuss methods and techniques for early detection of disease, the difference in monitoring for patients with DME, and the Vision Academy’s evidence-based guidance on monitoring the fellow eye.  To learn more about monitoring the fellow eye in patients with nAMD, read the Vision Academy Viewpoint, the Vision Academy slide deck, and the Vision Academy publication on current concepts and modalities for monitoring the fellow eye in nAMD.  For more information about patient-focused care, visit the nAMD Barometer and DR Barometer websites. If you enjoyed this episode, SUBSCRIBE to “A Chat with Anat” to make sure you never miss an episode!  Speaker disclosures: Professor Anat Loewenstein Consultant: 4DMT, AbbVie, Astellas, Bayer, Beyeonics, Eyepoint, Notal Vision, Ocular Therapeutix, Ocuphire, Oculis, Opthea, Roche, Boehringer-Ingelheim, Aviceda, Voiant Professor Paolo Lanzetta Consultant: Aerie, Allergan, Apellis, Bausch + Lomb, Bayer, Biogen, Boehringer Ingelheim, I-Care, Genentech, Novartis, Ocular Therapeutix, Outlook Therapeutics, and Roche  May 2025 PP-PF-OPHT-ALL-0219-1 Further information on topics discussed in this podcast: Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T; ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology. 2009 Jan;116(1):57─65.e5. Chew JK, Zhu M, Broadhead GK, Luo K, Hong T, Chang AA. Bilateral Neovascular Age-Related Macular Degeneration: Comparisons between First and Second Eyes. Ophthalmologica. 2017 Jan 1;238(1-2):23–30. Downey L, Acharya N, Devonport H, Gale R, Habib M, et al. Treatment choices for diabetic macular oedema: a guideline for when to consider an intravitreal corticosteroid, including adaptations for the COVID-19 era. BMJ Open Ophthalmol. 2021 Apr 27;6(1):e000696. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY; MARINA Stu This podcast series is intended for HCPs, and is not intended for UK audiences. Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing. This podcast series is produced and funded by Bayer. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise. The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer. The activities of the Barometer Program are funded and facilitated by Bayer where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program. The Vision Academy is a group of over 80 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer.

    20 min
  3. Choosing the right regimen for patients with nAMD

    APR 11

    Choosing the right regimen for patients with nAMD

    My guest for this special episode is Prof. Jean- François Korobelnik from the Department of Ophthalmology at the University Hospital, and at CHU Bordeaux, in Bordeaux, France. In this episode, Jean-François and I explore the importance of choosing the right regimen for our patients with nAMD. We discuss the evidence we can gather from clinical trials, and the lessons we learn from patients we see during clinical practice. We also explore the algorithm developed by the Vision Academy to choose the best regimen for patients. To learn more about how to choose the best treatment regimens to optimize outcomes for patients with nAMD, read the Vision Academy Viewpoint, and the accompanying slide deck. Please also visit the Vision Academy website. For more information about patient-focused care, visit the nAMD Barometer and DR Barometer websites. If you enjoyed this episode, SUBSCRIBE to “A Chat with Anat” to make sure you never miss an episode!  Speaker disclosures: Professor Anat Loewenstein Consultant: 4DMT, AbbVie, Astellas, Bayer, Beyeonics, Eyepoint, Notal Vision, Ocular Therapeutix, Ocuphire, Oculis, Opthea, Roche, Boehringer-Ingelheim, Aviceda, Voiant. Professor Jean- François Korobelnik Consultant: Abbvie, Adverum, Apellis, Bayer, Boehringer-Ingelheim, Carl Zeiss Meditec, Eyepoint Pharma, Ocular Therapeutix, Roche, SeaBeLife, Thea; member of the data safety monitoring board or advisory board for Alexion, Novo Nordisk, and Opthea. April 2025 PP-PF-OPHT-ALL-0215 -1 Further information on topics discussed in this podcast: Teo KYC, Eldem B, Joussen A, Koh A, Korobelnik JF, Li X, Loewenstein A, Lövestam-Adrian M, Navarro R, Okada AA, Pearce I, Rodríguez F, Wong D, Wu L, Zur D, Zarranz-Ventura J, Mitchell P, Chaudhary V, Lanzetta P. Treatment regimens for optimising outcomes in patients with neovascular age-related macular degeneration. Eye (Lond). 2024. doi: 10.1038/s41433-024-03370-0.  Gemenetzi M, Patel PJ. A Systematic Review of the Treat and Extend Treatment Regimen with Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration. Ophthalmol Ther. 2017;6:79-92.  Arnold JJ, Campain A, Barthelmes D, Simpson JM, Guymer RH, Hunyor AP, McAllister IL, Essex RW, Morlet N, Gillies MC; Fight Retinal Blindness Study Group. Two-year outcomes of "treat and extend" intravitreal therapy for neovascular age-related macul This podcast series is intended for HCPs, and is not intended for UK audiences. Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing. This podcast series is produced and funded by Bayer. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise. The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer. The activities of the Barometer Program are funded and facilitated by Bayer where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program. The Vision Academy is a group of over 80 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer.

    13 min
  4. Revolutionizing holistic patient care: Innovations and technologies

    JAN 8

    Revolutionizing holistic patient care: Innovations and technologies

    My guest for this special episode is Dr. John Kitchens, Vitreoretinal Surgeon with Retina Associates of Kentucky in the USA. In this episode, John and I explore the importance of holistic patient care. We also highlight the latest advances in home monitoring technologies in retinal disease, and how artificial intelligence (AI) can be used to aid in disease monitoring and optimization of clinic organization.  To learn more about the current status of AI in screening, diagnosing and managing retinal diseases, read the Vision Academy Viewpoint, and the Vision Academy retinal expert consensuses by clicking here or here. For more information about patient-focused care, visit the nAMD Barometer and DR Barometer websites. If you enjoyed this episode, SUBSCRIBE to “A Chat with Anat” to make sure you never miss an episode!  Speaker disclosures: Professor Anat Loewenstein- Consultant: Consultant for 4DMT, Abbvie, Alkeus, Annexon, Apellis, Astellas, Bayer health care, Beyeonics, Eyepoint, J & J, NotalVision, Novartis, Ocular Therapeutics, Ocuphire Pharma, Ocuterra, Oculis, Opthea, Oxurion, Roche, Syneos. Dr. John Kitchens - Consultant: Alcon, Allergan, Alimera, Apellis, Astellas, Bayer, Biogen, Bausch + Lomb, Genentech, Kodiak Bioscience, Notal Vision, Optos, Oculus, Outlook, Regeneron, Roche, and Zeiss. Speaker: Alcon, Bayer, Genentech, and Regeneron. Owns stock in Regeneron. Further information on topics discussed in this podcast: Age-Related Eye Disease Study Research Group. A Randomized, Placebo-Controlled, Clinical Trial of High-Dose Supplementation With Vitamins C and E, Beta Carotene, and Zinc for Age-Related Macular Degeneration and Vision Loss: AREDS Report No. 8. Arch Ophthalmol. 2001;119:1417–1436. The Age-Related Eye Disease Study 2 (AREDS2) Research Group, Chew EY, SanGiovanni JP, et al. Lutein/Zeaxanthin for the Treatment of Age-Related Cataract: AREDS2 Randomized Trial Report No. 4. JAMA Ophthalmol. 2013;131:843–850.  Anguita R, Ferro Desideri L, Loewenstein A, et al. The digital age in retinal practice. Int J Retina Vitreous. 2024 Sep 26;10:67. doi: 10.1186/s40942-024-00580-2.  January 2025 PP-PF-OPHT-ALL-0199-1 This podcast series is intended for HCPs, and is not intended for UK audiences. Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing. This podcast series is produced and funded by Bayer. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise. The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer. The activities of the Barometer Program are funded and facilitated by Bayer where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program. The Vision Academy is a group of over 80 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer.

    18 min
  5. Treatment futility and success in the context of suspending treatment

    11/07/2024

    Treatment futility and success in the context of suspending treatment

    My guest for this episode is Professor David Wong from the Department of Ophthalmology and Vision Sciences, University of Toronto and Unity Health Toronto in Toronto, Canada. In this episode, David and I discuss the Vision Academy’s algorithms for suspending treatment for nAMD in the context of treatment futility and success.  Our conversation highlights the monitoring considerations and criteria used to define treatment futility and success, and the potential of predictive biomarkers and at-home monitoring to optimize patient follow-up. Important resources, such as the Vision Academy Viewpoint and algorithm on suspending treatment of nAMD in cases of futility, can be found on the website. Or can be downloaded directly from here; view point and slide deck. Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing.  If you enjoyed this episode, SUBSCRIBE to ‘A Chat with Anat’ to never miss an episode! Further information on content in other podcasts in this series can be found here. Speaker disclosures: Professor Anat Loewenstein Consultancy: 4DMT, Abbvie, Alkeus, Annexon, Apellis, Astellas, Bayer health care, Beyeonics, Eyepoint, J & J, NotalVision, Novartis, Ocular Therapeutics, Ocuphire Pharma, Ocuterra, Oculis, Opthea, Oxurion, Roche, Syneos. Professor David Wong  Consultancy: Abbvie, Alcon, Apellis, Bayer, Bausch Health, Biogen, Boehringer Ingelheim, Novartis, Ripple Therapeutics, Roche, Topcon, and Zeiss; Research grants: Novartis and Roche. Further information on other studies mentioned in this episode: Wong DT, et al. SUSPENDING TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN CASES OF FUTILITY. Retina. 2020. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7448759/  June 2024 PP-PF-OPHT-ALL-0162-1 'A Chat with Anat' is a series for ophthalmologists who are interested in improving delivery of care and improved outcomes for patients living with neovascular age-related macular degeneration (nAMD). I’m Professor Anat Loewenstein, Chair of the Department of Ophthalmology at Tel Aviv Sourasky Medical Centre in Israel, and Professor of Ophthalmology and Vice Dean at Tel Aviv University. For each episode, I will be joined by internationally renowned colleagues to discuss key topics on patient-focused This podcast series is intended for HCPs, and is not intended for UK audiences. Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing. This podcast series is produced and funded by Bayer. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise. The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer. The activities of the Barometer Program are funded and facilitated by Bayer where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program. The Vision Academy is a group of over 80 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer.

    16 min
  6. World Sight Day and collaboration for change in eye health

    10/10/2024

    World Sight Day and collaboration for change in eye health

    My guest for this special episode is Peter Holland, Chief Executive of the International Agency for the Prevention of Blindness (IAPB). We speak about the importance of World Sight Day, and discuss how different initiatives, such as the Love Your Eyes campaign, have helped put eye health on the global agenda in collaboration with members and partners. We also highlight how clinicians can leverage their voices and influence to share knowledge, shape policies, and strengthen cross-sector collaborations, leading to the development of important resources for patients and clinicians to improve care. We recommend visiting the IAPB’s website, and the websites of the nAMD Barometer Program and Vision Academy for more information on World Sight Day, and resources to help you in your clinic.  If you enjoyed this episode, SUBSCRIBE to ‘A Chat with Anat’ to make sure you never miss an episode!  Speaker disclosures: Professor Anat Loewenstein Consultant: AbbVie, Bayer, Beyeonics, Syneos, Ripple, Iveric Bio, Johnson & Johnson, Ocuphire, Iqvia, Notal Vision, Novartis, and Roche. Peter Holland Employee: International Agency for the Prevention of Blindness. Further information on topics discussed in this podcast: Child eye health. The International Agency for the Prevention of Blindness. https://www.iapb.org/learn/vision-atlas/magnitude-and-projections/child-eye-health/. Accessed October 9, 2024. October 2024 PP-PFM-OPHT-ALL-0042-1 This podcast series is intended for HCPs, and is not intended for UK audiences. Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing. This podcast series is produced and funded by Bayer. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise. The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer. The activities of the Barometer Program are funded and facilitated by Bayer where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program. The Vision Academy is a group of over 80 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer.

    15 min
  7. Equal Vision – Women in Ophthalmology

    09/02/2024

    Equal Vision – Women in Ophthalmology

    My guests for this episode are Professor Sobha Sivaprasad, Consultant Ophthalmologist at Moorfields Eye Hospital and Professor of Retinal Clinical Studies at the UCL Institute of Ophthalmology in London, and Professor Gemmy Cheung, Professor and Senior Consultant Ophthalmologist at the Singapore National Eye Centre, Duke-NUS Medical School, National University of Singapore. In this special episode, we discuss our experiences as women working in ophthalmology, and the advice we would give to young, aspiring ophthalmologists. We also talk about what it meant to us to be named on The Ophthalmologist’s Power List, and how the next generation of ophthalmologists can be empowered through mentorship. We recommend visiting the Vision Academy Program website and nAMD Barometer Program website. We participate in these Programs to help develop important materials and training resources for clinicians and patients to improve patient-focused care and clinical practice. If you enjoyed this episode, SUBSCRIBE to ‘A Chat with Anat’ to never miss an episode! Further information on content in other podcasts in this series can be found here. Speaker disclosures: Professor Anat Loewenstein Consultancy: AbbVie, Bayer, Beyeonics, Syneos, Ripple, Iveric Bbio, Johnson & Johnson, Ocuphire, Iqvia, Notal Vision, Novartis, and Roche. Professor Sobha Sivaprasad  Consultancy: AbbVie, Amgen, Apellis, Bayer, Biogen, Boehringer Ingelheim, Novartis, Eyebiotech, Eyepoint Phamaceuticals, Janssen Pharmaceuticals, Nova Nordisk, Optos, Ocular Therapeutix, Kriya Therapeutics, OcuTerra, Roche, Stealth Biotherapeutics and Sanofi; Research grants: Bayer and Boehringer Ingleheim. Professor Gemmy Cheung Consultancy: Bayer, Roche, and Novartis. August 2024 PP-PF-OPHT-ALL-0164-1 Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing 'A Chat with Anat' is a series for ophthalmologists who are interested in improving delivery of care and improved outcomes for patients living with neovascular age-related macular degeneration (nAMD). I’m Professor Anat Loewenstein, Chair of the Department of Ophthalmology at Tel Aviv Sourasky Medical Centre in Israel, and Professor of Ophthalmology and Vice Dean at Tel Aviv University. For each episode, I will be joined by internationally renowned colleagues to discuss key topics on patient-focused care. This podcast series is sponsored and organised by Bayer and produced by Ap This podcast series is intended for HCPs, and is not intended for UK audiences. Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing. This podcast series is produced and funded by Bayer. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise. The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer. The activities of the Barometer Program are funded and facilitated by Bayer where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program. The Vision Academy is a group of over 80 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer.

    22 min
  8. Impact of residual fluid on treatment outcomes in nAMD

    08/08/2024

    Impact of residual fluid on treatment outcomes in nAMD

    In this episode, my guests Vision Academy and Barometer Program member Professor Jean-François Korobelnik, Professor and Head of the Ophthalmology Department at the University Hospital of Bordeaux in France, and Vision Academy member Professor Robyn Guymer, Deputy Director at the Centre for Eye Research and Professor of Ophthalmic at the University of Melbourne in Australia, discuss considerations for devising flexible and individualized treatment regimens for patients with nAMD with residual fluid. Using examples from their own clinical experience, Professors Korobelnik and Guymer explore the nuanced relationship between efficacy of anti-VEGF treatment and location and presence (or absence) of fluid in patients with nAMD. The Vision Academy Viewpoint providing recommendations for the assessment and monitoring of fluid status can be found on the website, along with other viewpoints and resources. Always refer to local treatment guidelines and relevant prescribing information. Please review the appropriate product information before prescribing. SUBSCRIBE to ‘A Chat with Anat’ to never miss an episode! Further information on content in other podcasts in this series can be found here.                     Speaker disclosures: Professor Jean-François Korobelnik  Consultancy: Abbvie, Allergan, Apellis, Bayer, Carl Zeiss Meditec, Janssen, NanoRetina, Roche, and Théa. Professor Robyn Guymer Advisory boards and/or Consultancy: Apellis, Bayer, Belite Bio, Boehringer Ingelheim Pharmaceuticals, Character Bioscience, Genentech, Novartis, Ocular Therapeutix, and Roche. Further information on residual fluid: Arnold J.J, et al. The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration - a phase IV randomised clinical trial with ranibizumab: the FLUID study. BMC Ophthalmol. 2016. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4806513/ Lek JJ., et al. Interpretation of subretinal fluid using OCT in intermediate age-related macular  degeneration. Ophthalmol Retina. 2018. https://www.sciencedirect.com/science/article/abs/pii/S2468653017307315?via%3Dihub  Hahn P, Eliott D, eds. 2021 Global Trends in Retina Survey. 2021. https://www.asrs.org/content/documents/202 This podcast series is intended for HCPs, and is not intended for UK audiences. Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing. This podcast series is produced and funded by Bayer. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise. The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer. The activities of the Barometer Program are funded and facilitated by Bayer where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program. The Vision Academy is a group of over 80 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer.

    27 min

About

"A Chat with Anat" is a series for ophthalmologists who are interested in improving delivery of care for patients living with retinal disease, and for those interested in clinically-challenging situations or controversies in care. I’m Professor Anat Loewenstein, Chair of the Department of Ophthalmology at Tel Aviv Sourasky Medical Centre in Israel, and Professor of Ophthalmology and Vice Dean at Tel Aviv University. For each episode, I will be joined by internationally renowned colleagues to discuss these important topics. This podcast series is sponsored and organized by Bayer and produced by ApotheCom. This podcast series is produced and funded by Bayer. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise. This is not intended for UK audiences. 

To listen to explicit episodes, sign in.

Stay up to date with this show

Sign in or sign up to follow shows, save episodes, and get the latest updates.

Select a country or region

Africa, Middle East, and India

Asia Pacific

Europe

Latin America and the Caribbean

The United States and Canada